StockMarketWire.com - AstraZeneca said Thursday that two clinical trials for its chronic kidney disease treatment both met their primary efficacy objectives.

The Olympus trial met its primary objective as AstraZeneca's chronic kidney disease treatment, Roxadustat, had demonstrated a 'statistically-significant and clinically-meaningful improvement in mean change from baseline in haemoglobin levels averaged over weeks 28 to 52 versus placebo,' the company said.

The Rockies trial, which assessed the efficacy and safety of roxadustat versus epoetin alfa, for the treatment of patients with anaemia in chronic kidney disease, who are dialysis dependent, also met its primary objective by demonstrating a statistically-significant improvement in mean change from baseline in haemoglobin levels averaged over weeks 28 to 52 versus epoetin alfa.

'Data from the Phase III Olympus and Rockies trials, together with the efficacy and pooled safety data from the global Phase III programme, will be part of the regulatory submission package in the US and other major countries,' AztraZeneca said.



Story provided by StockMarketWire.com